PMID- 20979567
OWN - NLM
STAT- MEDLINE
DCOM- 20110218
LR  - 20151119
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 10
IP  - 12
DP  - 2010 Dec
TI  - Personalized cancer vaccines.
PG  - 1637-47
LID - 10.1517/14712598.2010.531256 [doi]
AB  - IMPORTANCE OF THE FIELD: Personalized medicine has extended to management of 
      cancer and implies prescription of specific therapeutics best suited for an 
      individual patient and the type of tumor. These principles have been applied to 
      cancer vaccines. AREAS COVERED IN THIS REVIEW: Various cancer vaccines that can 
      be personalized. Tumor-derived vaccines have been used and active immunotherapy 
      based on antigens specific to the tumor. Dendritic cells (DCs) can prime 
      tumor-specific T cell responses and are considered potentially effective vaccines 
      for cancer. DCs may be genetically modified or fused with tumor cells. Adoptive 
      cell therapy is based on autologous antigen-specific T lymphocytes. Personalized 
      peptide vaccination has been combined with chemotherapy. Clinical trials have 
      been conducted. There have been many failures but a selection of those currently 
      in progress is presented. WHAT THE READER WILL GAIN: An overview of various types 
      of personalized cancer vaccines, their mechanism of action and current status of 
      development. Causes of failure of clinical trials and concepts of an ideal 
      personalized cancer vaccine are presented. TAKE HOME MESSAGE: A number of 
      approaches are available for personalized cancer vaccines with variable degree of 
      success. There are several challenges and needs for refinement of methods but it 
      remains a promising area of cancer therapy.
FAU - Jain, Kewal K
AU  - Jain KK
AD  - Jain PharmaBiotech, Basel, Switzerland. jain@pharmabiotech.ch
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101028
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes)
SB  - IM
MH  - Adoptive Transfer
MH  - Animals
MH  - Antigens, Neoplasm/genetics/immunology
MH  - *Cancer Vaccines
MH  - Dendritic Cells/immunology/transplantation
MH  - Epitopes
MH  - Genetic Therapy
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Immunotherapy, Active
MH  - Neoplasms/genetics/immunology/*therapy
MH  - Patient Selection
MH  - *Precision Medicine
MH  - Treatment Outcome
EDAT- 2010/10/29 06:00
MHDA- 2011/02/22 06:00
CRDT- 2010/10/29 06:00
PHST- 2010/10/29 06:00 [entrez]
PHST- 2010/10/29 06:00 [pubmed]
PHST- 2011/02/22 06:00 [medline]
AID - 10.1517/14712598.2010.531256 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2010 Dec;10(12):1637-47. doi: 
      10.1517/14712598.2010.531256. Epub 2010 Oct 28.